2020
Predictive classifier for intensive treatment of head and neck cancer
Zakeri K, Rotolo F, Lacas B, Vitzthum LK, Le Q, Gregoire V, Overgaard J, Hackshaw A, Zackrisson B, Parmar MKB, Burtness BA, Ghi MG, Sanguineti G, O’Sullivan B, Fortpied C, Bourhis J, Shen H, Harris J, Michiels S, Pignon J, Mell LK, Intergroup F. Predictive classifier for intensive treatment of head and neck cancer. Cancer 2020, 126: 5263-5273. PMID: 33017867, DOI: 10.1002/cncr.33212.Peer-Reviewed Original ResearchConceptsOverall survivalIntensive treatmentΩ scoreNeck cancerGood performance statusEffect of chemotherapyOral cavity sitesPerformance statusAdvanced headRandomized trialsControl armHigh riskN categoryPatientsRelative hazardYounger ageEvent riskEvent regressionCancerCancer progressionUnknown statusTreatment effectsChemotherapyScoresTreatment
2019
Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition
Miccio JA, Verma V, Kelly J, Kann BH, An Y, Park HS, Eskander A, Burtness B, Husain Z. Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. Oral Oncology 2019, 99: 104447. PMID: 31630059, DOI: 10.1016/j.oraloncology.2019.104447.Peer-Reviewed Original ResearchMeSH KeywordsAgedFemaleHumansLymph NodesMaleNeoplasm StagingOropharyngeal NeoplasmsPrognosisSurvival AnalysisConceptsOropharyngeal squamous cell carcinomaExtranodal extensionLymphovascular invasionKaplan-Meier overall survival analysisContralateral lymph node involvementHPV-positive oropharyngeal cancerFuture staging systemsNational Cancer DatabaseLymph node involvementLymph nodal involvementSquamous cell carcinomaAJCC eighth editionOverall survival analysisPathologic nodalInferior OSNodal involvementNode involvementWorse OSClinical stagingPrognostic factorsOropharyngeal cancerPositive marginsPrognostic importanceCell carcinomaCox regressionClinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy
LOGANADANE G, KANN BH, PARK HS, JOHNSON SB, MEHRA S, JUDSON BL, BHATIA A, BELKACEMI Y, YARBROUGH WG, BURTNESS B, HUSAIN ZA. Clinical Outcomes of Head and Neck Cancer Patients Who Undergo Resection, But Forgo Adjuvant Therapy. Anticancer Research 2019, 39: 4885-4890. PMID: 31519591, DOI: 10.21873/anticanres.13674.Peer-Reviewed Original ResearchConceptsLocoregional recurrence-free survivalAdjuvant therapyNeck squamous cell carcinomaOutcomes of patientsRecurrence-free survivalSquamous cell carcinomaNeck cancer patientsHNSCC patientsClinical outcomesRecurrence rateCell carcinomaMean TTPCancer patientsPatientsTherapyResectionMonthsOutcomesHNSCCSurgeryCarcinomaHeadIncidenceProgressionPathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment
Lee NCJ, Eskander A, Park HS, Mehra S, Burtness BA, Husain Z. Pathologic staging changes in oral cavity squamous cell carcinoma: Stage migration and implications for adjuvant treatment. Cancer 2019, 125: 2975-2983. PMID: 31090934, DOI: 10.1002/cncr.32161.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaPathologic extranodal extensionDepth of invasionAJCC Cancer Staging ManualCancer Staging ManualSquamous cell carcinomaOverall survivalPT3N0 patientsStage migrationStaging ManualCell carcinomaStaging systemAJCC-8 staging systemPathologic tumor classificationNational Cancer DatabaseRisk of deathNew staging systemPStage IVBUpstaged tumorsAdjuvant treatmentDefinitive surgeryExtranodal extensionPostoperative radiotherapyPT classificationPT1 tumors
2018
National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation
Morse E, Judson B, Husain Z, Burtness B, Yarbrough W, Sasaki C, Cheraghlou S, Mehra S. National treatment times in oropharyngeal cancer treated with primary radiation or chemoradiation. Oral Oncology 2018, 82: 122-130. PMID: 29909886, DOI: 10.1016/j.oraloncology.2018.02.010.Peer-Reviewed Original ResearchConceptsRadiation treatment durationHuman papilloma virus-positive tumorsVirus-positive tumorsOverall survivalOropharyngeal cancerTreatment durationTreatment endMedian durationTreatment initiationTreatment delayHuman papilloma virus-associated tumorsHuman papilloma virus-negative tumorsEnd intervalOropharyngeal squamous cell carcinomaCox proportional hazards regressionNational Cancer DatabaseProportional hazards regressionSquamous cell carcinomaVirus-associated tumorsVirus-negative tumorsMultivariable logisticHazards regressionCell carcinomaHuman papillomaCancer DatabaseUpfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer
Kelly JR, Park HS, An Y, Yarbrough WG, Contessa JN, Decker R, Mehra S, Judson BL, Burtness B, Husain Z. Upfront surgery versus definitive chemoradiotherapy in patients with human Papillomavirus-associated oropharyngeal squamous cell cancer. Oral Oncology 2018, 79: 64-70. PMID: 29598952, DOI: 10.1016/j.oraloncology.2018.02.017.Peer-Reviewed Original ResearchConceptsNational Cancer DatabasePrimary surgeryOverall survivalAdjuvant chemoradiotherapyDefinitive chemoradiotherapyUpfront surgerySurgical patientsHuman papillomavirus-associated oropharyngeal squamous cell carcinomaOropharyngeal squamous cell carcinomaPropensity score-matched analysisOropharyngeal squamous cell cancerCox proportional hazards regressionMultivariable Cox regressionNon-private insuranceInferior overall survivalMargin-negative resectionSquamous cell cancerProportional hazards regressionSquamous cell carcinomaLog-rank testChi-square testClinicopathologic predictorsSimilar OSSurgery patientsTrimodal therapy
2017
Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment
Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaNational Cancer Data BaseLate-stage diseasePrimary nonsurgical treatmentOral cavity malignancyNonsurgical treatmentSquamous cell carcinomaOverall survivalSurgical resectionCell carcinomaTreatment modalitiesNational Comprehensive Cancer Network Clinical Practice GuidelinesAcademic/research programMultimodality clinical trialsDefinitive radiation therapyImproved overall survivalDecreased overall survivalPrimary surgical resectionOral cavity cancerNon-randomized natureClinical practice guidelinesPatterns of careNon-white raceProportional hazards modelBinary logistic regressionHypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival
Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.Peer-Reviewed Original ResearchConceptsEarly-stage glottic cancerOverall survivalGlottic cancerMultivariable Cox proportional hazards regressionNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseCox proportional hazards regressionPropensity scoreClinical T1 diseaseImproved overall survivalHigh-volume centersProportional hazards regressionLog-rank testPatterns of careRadiation treatment schedulesLarge national databaseCT2 diseaseDefinitive radiotherapyT1 diseaseHypofractionated radiotherapyImproved survivalMultivariable analysisTreatment patternsHazards regressionNetwork guidelinesA Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma
Husain ZA, Chen T, Corso CD, Wang Z, Park H, Judson B, Yarbrough W, Deshpande H, Mehra S, Kuo P, Decker RH, Burtness BA. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma. JAMA Oncology 2017, 3: 358-365. PMID: 27737449, DOI: 10.1001/jamaoncol.2016.4581.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell cancerAJCC/UICC systemStaging systemStage IAStage IBHuman papillomavirusPrognostic abilityUICC systemAJCC/UICC staging systemStage IICurrent American Joint CommitteeOropharyngeal squamous cell carcinomaInternational Cancer Control (UICC) staging systemOropharyngeal cancer NetworkNational Cancer DatabasePrimary radiation therapyOverall survival rateAmerican Joint CommitteeCancer/UnionEdition staging systemKaplan-Meier methodSquamous cell cancerNovel staging systemSquamous cell carcinomaLog-rank test
2014
Predicting survival in head and neck squamous cell carcinoma from TP53 mutation
Masica DL, Li S, Douville C, Manola J, Ferris RL, Burtness B, Forastiere AA, Koch WM, Chung CH, Karchin R. Predicting survival in head and neck squamous cell carcinoma from TP53 mutation. Human Genetics 2014, 134: 497-507. PMID: 25108461, PMCID: PMC4324386, DOI: 10.1007/s00439-014-1470-0.Peer-Reviewed Original Researchp16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary
Keller LM, Galloway TJ, Holdbrook T, Ruth K, Yang D, Dubyk C, Flieder D, Lango MN, Mehra R, Burtness B, Ridge JA. p16 status, pathologic and clinical characteristics, biomolecular signature, and long‐term outcomes in head and neck squamous cell carcinomas of unknown primary. Head & Neck 2014, 36: 1677-1684. PMID: 24115269, PMCID: PMC3972378, DOI: 10.1002/hed.23514.Peer-Reviewed Original ResearchConceptsSquamous cell CUPNeck squamous cell carcinomaSquamous cell carcinomaUnknown primaryCell carcinomaTissue microarrayOverall survivalP16 statusHuman papillomavirus (HPV) statusMajority of patientsWorse overall survivalLong-term outcomesHPV associationP16 stainClinical characteristicsClinicopathologic characteristicsPrognostic factorsPrognostic featuresPrognostic implicationsExtracapsular extensionP16 stainingYounger ageCarcinomaP16High grade
2013
Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue
Sopka DM, Li T, Lango MN, Mehra R, Liu JC, Burtness B, Flieder DB, Ridge JA, Galloway TJ. Dysplasia at the margin? Investigating the case for subsequent therapy in ‘Low-Risk’ squamous cell carcinoma of the oral tongue. Oral Oncology 2013, 49: 1083-1087. PMID: 24054332, PMCID: PMC4037753, DOI: 10.1016/j.oraloncology.2013.08.001.Peer-Reviewed Original ResearchConceptsDisease-free survivalFox Chase Cancer CenterModerate dysplasiaOverall survivalLocal controlOral tongueSevere dysplasiaMild dysplasiaActuarial local controlInferior local controlKaplan-Meier methodOral tongue cancerWorse local controlSquamous cell carcinomaEarly-stage cancerAdditional therapyMeier methodResection marginsSubsequent therapyEntire cohortTongue cancerCancer CenterCell carcinomaPathology reportsFinal margins
2012
Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns
Galloway TJ, Lango MN, Burtness B, Mehra R, Ruth K, Ridge JA. Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns. Head & Neck 2012, 35: 160-164. PMID: 22302641, PMCID: PMC4037756, DOI: 10.1002/hed.22929.Peer-Reviewed Original ResearchMeSH KeywordsAge DistributionCarcinoma, Squamous CellDatabases, FactualFemaleFunctional LateralityHead and Neck NeoplasmsHumansIncidenceLymph NodesMaleNeoplasm InvasivenessNeoplasm StagingPapillomavirus InfectionsRetrospective StudiesRisk AssessmentSEER ProgramSex DistributionSurvival AnalysisTonsillar NeoplasmsUnited StatesConceptsBilateral neck diseaseHuman papillomavirus eraPrimary tonsillar cancerTonsillar cancerNeck diseaseAdvanced neck diseaseEnd Results ProgramNational Cancer InstituteCancer incidence dataIpsilateral diseaseAnnual incidenceResults ProgramRegional spread patternsBiologic behaviorCancer InstituteCancerDiseaseIncidence dataIncidenceSpread patternTherapyEpidemiology
2011
Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma
Pectasides E, Rampias T, Kountourakis P, Sasaki C, Kowalski D, Fountzilas G, Zaramboukas T, Rimm D, Burtness B, Psyrri A. Comparative Prognostic Value of Epidermal Growth Factor Quantitative Protein Expression Compared with FISH for Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research 2011, 17: 2947-2954. PMID: 21355076, DOI: 10.1158/1078-0432.ccr-10-2040.Peer-Reviewed Original ResearchCarcinomaCarcinoma, Squamous CellEpidermal Growth FactorFemaleGene DosageGene Expression Regulation, NeoplasticHead and Neck NeoplasmsHumansIn Situ Hybridization, FluorescenceMaleNeoplasms, Squamous CellPredictive Value of TestsPrognosisProteinsSquamous Cell Carcinoma of Head and NeckSurvival AnalysisTissue Array AnalysisA phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck
Argiris A, Ghebremichael M, Burtness B, Axelrod RS, Deconti RC, Forastiere AA. A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck. Cancer 2011, 117: 3374-3382. PMID: 21246525, PMCID: PMC3135694, DOI: 10.1002/cncr.25852.Peer-Reviewed Original ResearchConceptsAdenoid cystic carcinomaStable diseaseEvaluable patientsObjective responseCystic carcinomaEastern Cooperative Oncology Group performance status 0Day 1Common distant metastatic siteGrade 3 sensory neuropathyMedian progression-free survivalMetastatic adenoid cystic carcinomaGrade 3 anorexiaPerformance status 0Phase 2 trialProgression-free survivalTime of progressionSingle-agent bortezomibCombination of bortezomibDistant metastatic sitesAddition of doxorubicinMeasurable diseaseStatus 0Disease stabilizationFrequent toxicitiesPrior therapy
2010
Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting
Turaka A, Li T, Sharma NK, Li L, Nicolaou N, Mehra R, Burtness B, Cohen RB, Lango MN, Horwitz EM, Ridge JA, Feigenberg SJ. Increased Recurrences Using Intensity-Modulated Radiation Therapy in the Postoperative Setting. American Journal Of Clinical Oncology 2010, 33: 599-603. PMID: 21063195, DOI: 10.1097/coc.0b013e3181c4c3cc.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAgedAged, 80 and overCarcinoma, Squamous CellCohort StudiesFemaleHead and Neck NeoplasmsHumansIncidenceMaleMiddle AgedNeck DissectionNeoplasm Recurrence, LocalNeoplasm StagingPostoperative CarePostoperative PeriodPrognosisRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSex DistributionSurvival AnalysisTreatment FailureConceptsPatterns of failurePostoperative therapyRadiation therapyLocal failureMarginal failureNeck cancerRegional failureRetrospective single-institution studyFox Chase Cancer CenterHigh-risk PTVLocoregional failure rateAddition of chemotherapySingle-institution studySquamous cell carcinomaIntensity-modulated radiation therapyPersistence of diseaseLow-risk PTVConcurrent cisplatinCurative intentDefinitive radiationDefinitive RTNodal recurrencePostoperative settingMedian ageNodal stage
2009
Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals Of Oncology 2009, 20: 1242-1248. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.Peer-Reviewed Original ResearchConceptsAdvanced esophageal cancerPartial responseComplete responseEligible patientsEsophageal cancerEastern Cooperative Oncology Group performance statusMetastatic squamous cell carcinomaSafety of docetaxelPhase II trialSquamous cell carcinomaPrincipal toxic effectsAssessable patientsEsophagogastric cancerMeasurable diseaseToxic deathsII trialCN patientsMedian survivalPerformance statusNormal bilirubinPreclinical evidenceMedian timeCell carcinomaMyocardial infarctionTumor assessment
2008
A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study
Burtness BA, Manola J, Axelrod R, Argiris A, Forastiere AA. A randomized phase II study of ixabepilone (BMS-247550) given daily × 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. Annals Of Oncology 2008, 19: 977-983. PMID: 18296423, DOI: 10.1093/annonc/mdm591.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellCombined Modality TherapyDisease-Free SurvivalDocetaxelDrug Administration ScheduleDrug Resistance, NeoplasmEpothilonesFemaleHead and Neck NeoplasmsHematologic DiseasesHumansInfusions, IntravenousMaleMiddle AgedPaclitaxelPeripheral Nervous System DiseasesRecurrenceSalvage TherapySurvival AnalysisTaxoidsConceptsTaxane-naive patientsArm BEastern Cooperative Oncology Group performance statusEastern Cooperative Oncology Group StudyRecurrent squamous cell cancerSensory/motor neuropathyRandomized phase II studyMetastatic/recurrent diseaseCommon grade 3Grade 3 neuropathyPhase II studyPrimary end pointSquamous cell cancerSquamous cell carcinomaEligible patientsPrior regimensWeekly ixabepiloneRecurrent diseaseII studyMedian survivalPartial responsePerformance statusMotor neuropathyCell cancerCell carcinoma
2007
Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer
Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR. Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer. The Cancer Journal 2007, 13: 257-262. PMID: 17762761, DOI: 10.1097/ppo.0b013e31813c1174.Peer-Reviewed Original ResearchConceptsAdvanced pancreatic cancerPancreatic cancerEligible patientsIrinotecan combinationPartial responseComplete responseEastern Cooperative Oncology Group performance status 0Principal grade 3/4 toxicitiesWorld Health Organization criteriaSafety of docetaxelGrade 3/4 toxicitiesObjective response ratePerformance status 0One-year survivalPhase II trialCombination of docetaxelNormal bilirubin levelsEvaluable patientsFebrile neutropeniaMeasurable diseaseStatus 0Toxic deathsUnresectable diseaseII trialRecurrent diseasePhosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer
Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF, Haffty B, Kowalski D, Camp R, Rimm D, Vairaktaris E, Burtness B, Psyrri A. Phosphorylation of Akt (Ser473) Predicts Poor Clinical Outcome in Oropharyngeal Squamous Cell Cancer. Cancer Epidemiology Biomarkers & Prevention 2007, 16: 553-558. PMID: 17372251, DOI: 10.1158/1055-9965.epi-06-0121.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorCarcinoma, Squamous CellChi-Square DistributionFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedNeoplasm Recurrence, LocalOropharyngeal NeoplasmsPhosphorylationPredictive Value of TestsPrognosisProportional Hazards ModelsProtein Array AnalysisProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseSurvival AnalysisConceptsNuclear p-AktAkt activationP-AktOropharyngeal squamous cell cancerSquamous cell carcinoma progressionPhosphorylated AktCohort of patientsLocal recurrence rateOverall survival rateSquamous cell cancerPoor clinical outcomeAdverse patient outcomesP-AKT levelsPromising molecular targetP-AKT expressionProtein expression levelsPhosphorylation of AktDisease recurrenceLocal recurrenceCell cancerClinical outcomesAdjusted analysisPrognostic significanceRecurrence ratePatient outcomes